Navigation Links
Study shows chemotherapy improves survival among older breast cancer patients
Date:5/13/2009

The average age of a woman diagnosed with breast cancer is 63, so it is critical to have effective proven, therapies for an older patient population. But older women with breast cancer are underrepresented in clinic trials, so there is little data on the effects of chemotherapy used in addition to other therapies such as surgery.

A new study, published in the May 14 issue of The New England Journal of Medicine, shows that chemotherapy in addition to the surgery or surgery and radiation improves survival among older women.

The study was conducted with 600 women through the Cancer and Leukemia Group B of the National Cancer Institute's Clinical Trials Cooperative Group Program.

"This study is important because it is among the first several trials specifically targeted to older women with early-stage breast cancer and shows that chemotherapy can make a difference," said Hyman Muss, M.D. professor of medicine at the University of North Carolina at Chapel Hill and a member of UNC Lineberger Comprehensive Cancer Center, and corresponding author on the study.

The study compared a combination of chemotherapy drugs the standard treatment to a single drug in patients with early-stage breast cancer aged 65 and older. The combination therapy provided significantly better outcomes than a single drug treatment.

Similar studies involving women younger than 70 years of age have also shown that combination therapies provide better outcomes.

For this trial, the standard chemotherapy consisted of either cyclophosphamide, methotrexate, and fluouracil (CMF) or doxorubicin plus cyclophosphamide. The single drug was the oral drug, capecitabine.

Because patients often prefer oral to intravenous chemotherapy, a new effective oral agent for multi-drug treatment would be useful in treating older women with breast cancer. But the study showed that patients who were randomly assigned to capecitabine were twice as likely to have a relapse, and at three-years after completing therapy, the rate of relapse-free survival was 68 percent in the capecitabine group versus 85 percent in the standard-chemotherapy group.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. New research confirms milestone study on blood pressure meds
2. UCLA study shows traumatic brain injury haunts children for years
3. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
4. A feasible, simple and convenient model for study of rectal carcinoma
5. New Study Shows Stresses of Economic Downturn on Womens Relationships
6. New Economic Impact Study: Obama Administration Implementation of Bush-Era Medicare Regulation Will Cost U.S. $2.5 Billion in Business Activity, Cut Over 30,000 Jobs
7. 22-year study finds adults arent active enough
8. Researchers study the human factor in spread of pandemic illness
9. Eye Disease, Cognitive Decline Linked in Study
10. Access to care leads Americans priorities in first-ever public study of health value
11. Access to Care Leads Americans Priorities in First-Ever Public Study of Health Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently becoming ... require expert user knowledge. In a live webinar on April 11th and October ... highly accurate, determination of sodium. , It has long been known that too ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... ... has entered a settlement agreement to resolve the pending litigation between itself and ... for the District of Utah). , “I am thrilled to announce that we ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/27/2017)... ... , ... Harris Communications, Inc., a leading provider of assistive technology for ... Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in Houston. ... staff from Harris Communications and to try out the newest assistive devices available to ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden Media ... All through the year, Garden Media aims to provide material helpful to clients’ goals ... pitching client’s key messages to gain coveted media placements, Garden Media wows ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Therapix Biosciences Ltd. (NASDAQ: ... the development of cannabinoid-based drugs, today announced the ... the United States of 2,000,000 American ... shares of the Company, at a price of ... the underwriters a 45-day over-allotment option to purchase ...
(Date:3/27/2017)... March 27, 2017  A recent study at Shriners ... freestanding hospitals in the country dedicated to the treatment ... surgery, concluded that the Surfacide Helios ® UV-C ... in reducing bacterial pathogens not killed by the EVS ... at the American Burn Association,s 49th Annual Meeting in ...
(Date:3/27/2017)... March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... passed early toxicology and efficacy studies. The company is ... a specific protein, MAGE A, in an effort to ... After 4 weeks of treatment in ... very little toxicity in a full toxicology report of ...
Breaking Medicine Technology: